A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
Condition(s) studied
Investigational drug(s) / intervention(s)
AGTC-501 (high dose and standard corticosteroid regimen): Adeno-associated virus vector expressing a human RPGR gene
AGTC-501 (low dose and standard corticosteroid regimen): Adeno-associated virus vector expressing a human RPGR gene
AGTC-501 (high dose and modified corticosteroid regimen): Adeno-associated virus vector expressing a human RPGR gene
Study summary
This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.
Eligibility
Primary outcome measure(s)
- The primary safety outcome is the number of participants experiencing Grade 3 or higher local (ocular) or non-ocular treatment-emergent adverse events, including treatment-emergent serious adverse events (SAEs). — Day 0 - Month 12
- The primary safety outcome is the proportion of participants experiencing Grade 3 or higher local (ocular) or non-ocular treatment-emergent adverse events, including treatment-emergent serious adverse events (SAEs). — Day 0 - Month 12
Trial sites (7)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Florida | Jacksonville | Florida | |
| Bascom Palmer Eye Institute | Miami | Florida | |
| Boston Children's Hospital | Boston | Massachusetts | |
| Cincinnati Eye Institute | Cincinnati | Ohio | |
| Cleveland Clinic | Cleveland | Ohio | |
| Casey Eye Institute | Portland | Oregon | |
| Retina Foundation of the Southwest | Dallas | Texas |
More Beacon Therapeutics trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06275620 on ClinicalTrials.gov ↗ ← All trials in the USA